- NEWS AND VIEWS
Natural killer cells lull tumours into dormancy
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature 594, 501-502 (2021)
doi: https://doi.org/10.1038/d41586-021-01381-5
References
Mohme, M., Riethdorf, S. & Pantel, K. Nature Rev. Clin. Oncol. 14, 155–167 (2017).
Correia, A. et al. Nature 594, 566–571 (2021).
Chiossone, L., Dumas, P.-Y., Vienne, M. & Vivier, E. Nature Rev. Immunol. 18, 671–688 (2018).
Daher, M. & Rezvani, K. Cancer Discov. 11, 45–58 (2021).
Myers, J. A. & Miller, J. S. Nature Rev. Clin. Oncol. 18, 85–100 (2021).
López-Soto, A., Gonzalez, S., Smyth, M. J. & Galluzzi, L. Cancer Cell 32, 135–154 (2017).
Molgora, M. et al. Nature 551, 110–114 (2017).
Malladi, S. et al. Cell 165, 45–60 (2016).
Tsuchida, T. & Friedman, S. L. Nature Rev. Gastroenterol. Hepatol. 14, 397–411 (2017).
Shi, Y., Riese, D. J., 2nd & Shen, J. Front. Pharmacol. 11, 574667 (2020).
Dadi, S. et al. Cell 164, 365–377 (2016).
Gao, Y. et al. Nature Immunol. 18, 1004–1015 (2017).
Gauthier, L. et al. Cell. 177, 1701–1713 (2019).
Competing Interests
E.V. is a shareholder and employee of Innate Pharma.